top of page

Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

Novartis (NOVN.S) breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly (LLY.N).


Featured Posts
Recent Posts
Search By Tags
bottom of page